1. |
Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: pathology and biology. Semin Hematol, 2016, 53(3): 139-147.
|
2. |
Gupta S, Craig JW. Classic Hodgkin lymphoma in young people. Semin Diagn Pathol, 2023, 40(6): 379-391.
|
3. |
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol, 1989, 7(11): 1630-1636.
|
4. |
Belsky JA, Hochberg J, Giulino-Roth L. Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults. Best Pract Res Clin Haematol, 2023, 36(1): 101445.
|
5. |
de Armas S, Huertas-Ayala C, Chan RY, et al. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. Pediatr Blood Cancer, 2022, 69(5): e29601.
|
6. |
Geel JA, Chirwa TC, Rowe B, et al. Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: first report by the South African Children's Cancer Study Group. Pediatr Blood Cancer, 2017, 64(10): e26536.
|
7. |
Nayak L, Jain H, Bonda A, et al. Hodgkin lymphoma in adolescent and young adults: real-world data from a single tertiary cancer center in India. J Adolesc Young Adult Oncol, 2021, 10(5): 581-587.
|
8. |
Hatam N, Dehghani M, Habibian M, et al. Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory Hodgkin and non-Hodgkin's lymphoma in Iran. Iran J Cancer Prev, 2015, 8(5): e4061.
|
9. |
田艳平, 崔向丽, 刘丽宏, 等. 基于决策树模型对我国6种保肝药物治疗药物性肝损伤的成本-效果分析. 中国药物应用与监测, 2018, 15(3): 131-135.
|
10. |
Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, et al. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol, 2023, 24(3): 252-261.
|
11. |
Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group. Cancer, 2018, 124(15): 3210-3219.
|
12. |
吴彬, 王娟, 朱佳, 等. 85例儿童和青少年局限期霍奇金淋巴瘤临床分析. 中华血液学杂志, 2020, 41(8): 649-654.
|
13. |
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol, 2022, 23(1): 125-137.
|
14. |
Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol, 2014, 32(32): 3651-3658.
|
15. |
Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol, 2019, 187(1): 39-48.
|
16. |
Jain S, Bakhshi S, Seth R, et al. Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01. Leuk Lymphoma, 2022, 63(5): 1111-1118.
|
17. |
Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 2011, 117(9): 2596-2603.
|
18. |
Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother, 2021, 22(12): 1579-1592.
|
19. |
Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. J Clin Oncol, 2023, 41(12): 2248-2257.
|
20. |
de Baat EC, van Dalen EC, Mulder RL, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health, 2022, 6(12): 885-894.
|
21. |
Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 2009, 27(1): 127-145.
|
22. |
Liang DC. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatr Drugs, 2003, 5(10): 673-684.
|
23. |
Flerlage JE, Hiniker SM, Armenian S, et al. Pediatric Hodgkin lymphoma, version 3. 2021. J Natl Compr Canc Netw, 2021, 19(6): 733-754.
|
24. |
Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol, 1994, 12(10): 2160-2166.
|
25. |
Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages ⅡB, ⅢA2, ⅢB, and Ⅳ Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol, 1997, 15(8): 2769-2779.
|
26. |
Donaldson SS. Finding the balance in pediatric Hodgkin's lymphoma. J Clin Oncol, 2012, 30(26): 3158-3159.
|
27. |
Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol, 2012, 157(1): 3-13.
|
28. |
Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa. Leuk Lymphoma, 2009, 50(2): 196-199.
|
29. |
Soliman R, Oke J, Sidhom I, et al. Cost-effectiveness of childhood cancer treatment in Egypt: lessons to promote high-value care in a resource-limited setting based on real-world evidence. EClinicalMedicine, 2022, 55: 101729.
|
30. |
Neal C, Rusangwa C, Borg R, et al. Cost of treating pediatric cancer at the Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol, 2018, 4: 1-7.
|
31. |
Genemo I, Chala TK, Hordofa DF, et al. Cost and cost-effectiveness of treating childhood cancer at Jimma Medical Center. Clinicoecon Outcomes Res, 2023, 15: 433-442.
|
32. |
王芳旭, 陶立波, 董咚, 等. 中国霍奇金淋巴瘤患者疾病负担调查—基于一项在线问卷调查的研究. 中国医疗保险, 2020, (1): 60-64.
|
33. |
陈敏, 喻佳洁, 向桐煜, 等. 依托泊苷/达卡巴嗪进入WHO儿童药物基本目录治疗儿童霍奇金淋巴瘤有效性、安全性和经济性的循证快速评估. 中国药房, 2018, 29(19): 2593-2597.
|